Dara IV
PreclinicalSmall molecule
Johnson & JohnsonDara IV is one of 21 small molecule programs targeting AL amyloidosis. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in AL Amyloidosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Decadron
AAspen Global Incorporated
Phase 3
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Cordarone
WWyeth-Lederle Vaccines
Approved
DARZALEX FASPRO
Johnson & JohnsonPhase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Alkeran
AApotex Inc.
Phase 3
Tecvayli
Johnson & JohnsonPhase 2
Ninlaro
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dara IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company